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Higher levels of circulating soluble (s)ST2, another marker of cardiac stress, have been associated with risk of heart failure after acute myocardial infarction, 15 mortality in patients with ST-segment-elevation myocardial infarction, 16 mortality in patients with heart failure, 17 and with incident overall CVD, heart failure, and all-cause mortality in population-based cohorts. 12 Concentrations of sST2 are positively associated with high age, male sex, hypertension, and diabetes mellitus in the community. 18 Despite much evidence suggesting a role for GDF-15 and sST2 in risk prediction of adverse CVD outcomes in different settings, no previous study has specifically assessed the relationships of circulating GDF-15 and sST2 concentrations with cerebrovascular disease. We, therefore, investigated the association of circulating GDF-15 and sST2 levels with the risk of developing clinical stroke prospectively, and with the risk of subclinical vascular brain injury on brain MRI and neuropsychological assessment cross-sectionally in a large communitybased sample.
Methods
Study Sample
The present analysis was based on participants from the Framingham Offspring Study, which began in 1971 with the enrollment of 5124 individuals. 19 Of the 3532 participants who attended the sixth examination cycle (1995) (1996) (1997) (1998) , 3456 had available biomarker measurements for GDF-15 and sST2. We constructed 2 study samples for our analysis, each a subset of the 3456 participants with available biomarker data. After the seventh examination cycle (1999) (2000) (2001) (2002) (2003) (2004) (2005) , all participants were invited to undergo a brain MRI scan and concurrent neuropsychological test battery. Of the 3456 participants with biomarker data, 2591 completed the MRI/neuropsychological testing (characteristics of patients with and without MRI are shown in Table I in the online-only Data Supplement; in general, patients with MRI data had a less adverse cardiovascular risk profile). Of these, we excluded an additional 61 participants for prevalent stroke, 34 for prevalent dementia, and 33 for other neurological conditions (such as brain tumors or multiple sclerosis, which could influence the MRI measures), resulting in a sample size of 2463 for our cross-sectional analysis of MRI/neuropsychological outcomes. For our analysis of the stroke/transient ischemic attack (TIA) outcome, of the 3456 participants with biomarker data, we excluded 76 participants with prevalent stroke and 6 participants without follow-up information, resulting in a sample size of 3374 for these prospective analyses.
Biomarker Measurements
The GDF-15 and sST2 biomarkers were measured on previously unthawed fasting blood samples that had been centrifuged and stored at −80°C. GDF-15 concentrations were obtained from a precommercial immunoassay on a Cobas e 411 analyzer (Roche Diagnostics, Switzerland), and sST2 concentrations were measured using an enzyme-linked immunosorbent assay (Presage ST2; Critical Diagnostics, San Diego, CA). Details of these laboratory analytic methods have been previously described. [20] [21] [22] 
MRI and Neuropsychological Test Outcome Measures
A full description of the MRI measures, including interobservational variability, has been published previously. 23 Experts blinded to demographic and clinical information analyzed all images in a core laboratory using custom-written software. Total cerebral brain volume (TCBV) was calculated as the ratio between TCBV and total intracranial volume. A lower ratio, therefore, indicates relative brain atrophy. Cumulative volume of white-matter hyperintensity lesions (WMHIV) was quantified by an automated method and divided by cerebral brain volume. Because of a skewed distribution, WMHIV was natural log (ln) transformed in our analyses.
Participants were also invited to complete a battery of neuropsychological tests (1999) (2000) (2001) on the same date as the brain MRI.
The tests used and scoring system have been detailed previously. 24 In accordance with previous studies, 25, 26 we related the circulating biomarkers to scores on 2 cognitive tests known to be sensitive to vascular brain injury, that is, visual reproduction-delayed recall and the Halstead-Reitan trail making tests on which we used the difference between scores on the trail B and trail A tests as a measure of executive function subtracting out the elements of the score related to attention, visual scanning, and motor tracking that were common to both trails B and A.
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Incident Stroke/TIA All individuals have been followed up with clinical examinations every 3 to 6 years and are under continuous surveillance for incident CVD, stroke, dementia, and mild cognitive impairment. All potential stroke events have been reviewed by a stroke end-point review committee comprised of at least 2 neurologists. We defined incident stroke as an acute onset focal deficit of presumed or definite vascular cause of >24-hour duration. We defined a TIA as a similar clinical presentation but lasting for a duration of ≤24 hours.
Covariate Measurements
Information of covariates was obtained at examination cycle 6. We used variables included in the Framingham stroke risk score profile to adjust for established risk factors for vascular brain injury. These included systolic blood pressure, use of antihypertensive medications, diabetes mellitus, current smoking, CVD (coronary heart disease, heart failure, or intermittent claudication), and atrial fibrillation. 28 The Framingham stroke risk score profile score has previously been associated with smaller brains and poorer cognitive function in the present cohort, as well as with incident stroke in the original cohort. [27] [28] [29] We categorized the highest achieved educational status into 4 groups: <high school degree, high school degree only, some college, or ≥col-lege degree. Other biomarkers, including high-sensitivity C-reactive protein, B-type natriuretic peptide, and urine albumin were measured at the sixth examination cycle.
Ethics
All study participants provided written, informed consent, and the study protocol was approved by the institutional review board for human research at the Boston University Medical Center.
Statistical Analyses
Any variable with a skewed distribution was natural logarithmically (ln) transformed. Linear regression models were constructed to examine the association between the GDF-15 and sST2 biomarkers and the following outcomes: (1) brain MRI measures (TCBV and WMHIV) and (2) neuropsychological test measures (visual reproduction-delayed recall and trail B-trails A). Cox regression models were performed to assess the longitudinal associations of GDF-15 and sST2 with incident total stroke/TIA and with ischemic stroke, using calendar time as the time scale and after confirming that the assumption of proportionality of hazards was met. The GDF-15 and sST2 biomarkers were entered into the models both as continuous variables and as quartiles (in separate analyses). A test for linear trend across biomarker quartiles was conducted by entering an ordinal variable (representing the biomarker quartiles) into the model and calculating a Wald P value. Three multivariable regression models were constructed. Model 1 adjusted for sex and age (and age squared for MRI measures), education group (for neuropsychological test outcomes), and time between examination 6 (where blood was drawn) and MRI/ neuropsychological tests (for those analyses). Model 2 additionally adjusted for variables in the Framingham stroke risk score profile. Model 3 additionally adjusted for other biomarkers, viz, B-type by guest on July 13, 2017 http://stroke.ahajournals.org/ Downloaded from natriuretic peptide, high sensitivity C-reactive protein, and urine albumin concentrations, because these biomarkers have been shown to be associated with subclinical brain damage and predict incident vascular brain injury and stroke in the present cohort (beyond traditional risk factors). 30 All analyses were performed using SAS version 9.4 (Cary, NC). A 2-sided P value of <0.05 was considered as statistically significant for all tests.
Results
The analysis included 2463 participants for the neuropsychological test outcomes, 2128 for the MRI brain measure outcomes, and 3374 for the incident stroke/TIA outcome.
Approximately 53% of our study sample was women, and the overall mean age was 59 (±SD10) years. Baseline characteristics of the study samples are shown in Table 1 . The prevalence of CVD risk factors was rather high, with 27% being treated with antihypertensive medications, 10% having diabetes mellitus, 15% being current smokers, and 9% having prevalent CVD.
Brain MRI Measure Outcomes
Higher concentrations of GDF-15 and sST2 were each significantly associated with lower levels of TCBV in all 3 multivariable models ( Table 2) . Adjustment for traditional cardiovascular risk factors, as well as B-type natriuretic peptide, high-sensitivity C-reactive protein, and urine albumin levels (models 2 and 3) attenuated the β coefficients for the biomarkers of interest, but they remained statistically significant (β coefficients for TCBV comparing fourth [Q4] versus first biomarker [Q1] quartiles, −0.71% for GDF-15; P=0.002 [P value for linear trend=0.004] and 0.47% for sST2; P=0.02 [P value for linear trend=0.02]). GDF-15 was positively associated with higher ln-WMHIV, β=0.19, P=0.01 for the Q4 versus Q1 (P value for linear trend=0.01) in fully-adjusted models ( Table 2 ). There was no association between sST2 and WMHIV in any of the models evaluated.
Neuropsychological Test Outcomes
Higher concentrations of GDF-15 and sST2 were associated with poorer delayed visual reproduction test results (Table 3) : β coefficients for Q4 versus Q1=−0.62, P=0.009 for GDF-15 (P value for linear trend=0.01) and −0.40, P=0.04 for sST2 (P value for linear test=0.10) in fully-adjusted models. In analyses adjusted for age and sex, higher GDF-15 concentrations were associated with lower results on trail B-trail A, but after additional adjustment, the associations were no longer statistically significant.
Exploratory Analyses
To better understand the associations of biomarkers with TCBV and neuropsychiatric tests, we investigated whether the strength of association between biomarkers and the aforementioned measurements differed between patients with and without extensive WMHIV (defined as a WMHIV >1.5 SD above the age-and sex-adjusted mean). For TCBV, the association with GDF-15 concentrations was stronger among those with, compared with those without extensive WMHIV, P value for interaction of <0.0001 (Table II in the online-only Data Supplement). For trail B-trail A, associations with both of GDF-15 and sST2 levels were stronger among those with compared with those without extensive WMHIV (P value for interactions=0.02 and 0.03, respectively).
Incident Stroke Outcome
During a mean follow-up of 11.8±3.0 years, 203 (6%) participants developed stroke/TIA (130 had ischemic stroke). sST2 and GDF-15 levels were both associated with incident stroke/ TIA in models adjusted for age and sex ( 
Discussion
In the present investigation, we observed that higher concentrations of circulating GDF-15 and sST2 were associated with several measures indicative of subclinical brain damage and other concomitant neurodegenerative processes in a sample of middle-aged ambulatory individuals without previous stroke or dementia. sST2 was also observed to be a strong long-term predictor of incident stroke/TIA beyond traditional risk factors plus biomarkers that have previously been documented to predict incident stroke in the Framingham Heart Study (ie, B-type natriuretic peptide, high-sensitivity C-reactive protein, and urine albumin). 30 Wang et al 12 have previously investigated the relationship of higher GDF-15 and sST2 concentrations with incident heart failure, major coronary events, and a composite CVD outcome (comprising recognized myocardial infarction, coronary insufficiency, coronary heart disease death, heart failure, and stroke) in the Framingham Offspring cohort. Interestingly, both biomarkers could predict events above and beyond established risk factors for all end points except for major coronary events. Based on this, it has been hypothesized that GDF-15 and sST2, in ambulatory individuals, are related to cardiac stress/dysfunction rather than atherosclerotic manifestations and subclinical inflammation. 
GDF-15, Subclinical Vascular Brain Injury, and Incident Stroke
Several lines of evidence also suggest that GDF-15 may be associated with endothelial dysfunction and small vessel disease. In our exploratory analyses, blood GDF-15 levels showed stronger associations with TCBV and trail B-trail A among those with, compared with those without extensive WMHIV, which may suggest that GDF-15 may be primarily reflective of cerebral microvascular disease in population-based settings (because extensive WMHIV is a marker of microvascular disease). GDF-15 has also been associated with microvascular disease in noncerebral vascular beds. In the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS), circulating GDF-15
concentrations were directly associated with endotheliumdependent vasodilation in resistance vessels. 4 By comparing endothelial function in wild-type and GDF-15 knocked out mice, GDF-15 was recently demonstrated to directly modulate the endothelial-dependent nitric oxide synthase pathway in the aortas of mice. 31 Our observations are also in agreement with other lines of evidence suggesting a significant role of GDF-15 in vascular brain injury. For instance, higher GDF-15 levels have previously been reported to be strongly related to worse functional status in the acute phase of ischemic stroke in humans. 10 Mouse models of cerebral ischemia have also demonstrated upregulation in GDF-15 expression (possible by neurons) 32 secondary to vascular brain damage. 33 In contrast, GDF-15 does not seem to be expressed in mice with normal brain circulation. 33 In vivo, GDF-15 seems to prevent certain types of neural losses in rats, 34 and a recent study of elderly community-based individuals (mean age, 78-81 years) demonstrated an inverse association of higher GDF-15 concentrations with cognitive function. 35 Because subclinical vascular brain damage increases the risk of dementia and is associated with a steeper decline in cognitive function among elderly individuals, one mechanism that could link high GDF-15 levels with impaired cognitive function may be via its association with subclinical vascular brain injury. 36, 37 In this context, blood GDF-15 levels were recently reported to also be associated positively with gray matter volume decline for a 2-year period in an elderly community-based sample. 38 Somewhat surprising, yet in line with the previous study by Wang et al 12 (showing no association of GDF-15 with incident coronary events), we observed no association of blood GDF-15 levels with incident stroke/TIA in our sample. This is also in agreement with results from a previous Swedish population-based sample of men (mean age, 71 years). Adjusted for multiple risk factors, GDF-15 concentrations were not associated with stroke or stroke-related mortality in this latter study. We observed statistically significant associations between higher concentrations of sST2 and lower TCBV and poorer delayed visual reproduction test result. We also observed an increased risk of stroke with higher sST2 levels after adjustment for established stroke risk factors (although the end point with overt stroke was only borderline statistically significant). sST2 has previously predominantly been studied in the setting of heart failure, and to the best of our knowledge, no previous study has investigated the relationship of sST2 with subclinical vascular brain damage and incident stroke. In point of fact, reports relating sST2 to the central nervous system are sparse. Experimental studies have demonstrated that sST2 may be produced by astrocytes and endothelial cells and can activate microglia and enhance phagocytosis, which could both be important responses to vascular injury. 40 As noted above, neither GDF-15 nor sST2 concentrations have previously been shown to be significantly associated with coronary events in Offspring cohort. 12 In contrast to GDF-15, we observed an association of sST2 with incident stroke in our study. Whether sST2 is more specific than GDF-15 for vascular brain damage and inflammation is not known. Our observation could also be related to the strong association of sST2 with incident heart failure because heart failure and atrial fibrillation (which is common in patients with heart failure) are strong risk factors for incident stroke. Circulating sST2 has, however, not been linked to incident atrial fibrillation in the present study sample. 21 We also previously reported that concentrations of sST2 predict incident systolic blood pressure in this cohort; despite adjustment for prevalent hypertension in our models, it may be this explains the stronger links to cerebrovascular disease than GDF-15.
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Strengths and Limitations
The main strength of our study was the comprehensive phenotypic data available in the Framingham Offspring cohort, which enabled us to study both subclinical and clinical vascular brain injury in relation to biomarkers. Another strength is that incident stroke events have been adjudicated and are accurate. However, some limitations merit consideration. The number of strokes in the present investigation was rather limited, and therefore, a type II statistical error cannot be excluded. Also, the stroke subtypes could not be separately analyzed because of the small sample sizes for individual subtypes. For the MRI/ neuropsychological analyses, the study sample comprised people who had attended both the sixth examination cycle and had undergone MRI/neuropsychological testing an average of 4 years later. Furthermore, the temporal differences between MRI/neuropsychological testing and biomarker assays may have lead to regression dilution bias, which may have underestimated the true strength of the association of biomarkers and brain measures. Finally, the sample was predominantly white and middle-aged, and the generalizability of our findings to other age groups and other races is unknown.
Conclusions and Clinical Implications
Circulating concentrations of GDF-15 and sST2 are associated with subclinical brain damage cross-sectionally, and sST2 is also associated with incident stroke/TIA prospectively after adjustment for established risk factors. Our study should be viewed as only hypothesis-generating, but if confirmed, these associations could point to novel stroke and vascular brain injury prediction models and prevention strategies targeting these pathways.
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Online supplemental †Natural log (ln) transformed *P-value for interaction between biomarker and extensive white matter hyperintensities (yes vs. no) **Models are adjusted for age at MRI, age at MRI squared, sex, time between examination 6 and MRI, FSRP components (systolic blood pressure, hypertension treatment, diabetes, smoking, history of CVD, history of AF), BNP, hsCRP, and urine albumin. ***Models are adjusted for age at NP, sex, education group (<high school degree, high school degree, ≥college graduate) and time between examination 6 and NP, FSRP components (systolic blood pressure, hypertension treatment, diabetes, smoking, history of CVD, history of AF), BNP, hsCRP, and urine albumin.
